CARDIOVASCULAR RISK REDUCTION BY REVERSING ENDOTHELIAL DYSFUNCTION: ARBS, ACE INHIBITORS,  OR BOTH? EXPECTATIONS FROM THE ONTARGET  TRIAL PROGRAMME

Luis Miguel  Ruilope1, Josep Redón2, Roland Schmieder31Servicio de Nefrologia, Unidad de Hipertension Hospital, 12 Salad Plate de Octubre, Madrid, Spain; 2Department of Internal Medicine, Hospital Clinico University of Valencia, Valencia, Spain; 3Department of Nephrology and Hypertension, Friedrich-Alexander-Universitat, Erlangen-Nurnbe

The tumor microenvironment (TME) is a heterogeneous ecosystem comprising cancer cells, immune cells, stromal cells, and various non-cellular components, all of which play critical roles in controlling tumor progression and response to immunotherapies.Methyltransferase-like 3 (METTL3), the core component of N6-methyladenosine (m6A) writer, is freque